Medical Care Costs and Quality of Life after Randomization to Coronary Angioplasty or Coronary Bypass Surgery
- 9 January 1997
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 336 (2) , 92-99
- https://doi.org/10.1056/nejm199701093360203
Abstract
Randomized trials comparing coronary angioplasty with bypass surgery in patients with multivessel coronary disease have shown no significant differences in overall rates of death and myocardial infarction. We compared quality of life, employment, and medical care costs during five years of follow-up among patients treated with angioplasty or bypass surgery. A total of 934 of the 1829 patients enrolled in the randomized Bypass Angioplasty Revascularization Investigation participated in this study. Detailed data on quality of life were collected annually, and economic data were collected quarterly. During the first three years of follow-up, functional-status scores on the Duke Activity Status Index, which measures the ability to perform common activities of daily living, improved more in patients assigned to surgery than in those assigned to angioplasty (P<0.05). Other measures of quality of life improved equally in both groups throughout the follow-up period. Patients in the angioplasty group returned to work five weeks sooner than did patients in the surgery group (P<0.001). The initial mean cost of angioplasty was 65 percent that of surgery ($21,113 vs. $32,347, P<0.001), but after five years the total medical cost of angioplasty was 95 percent that of surgery ($56,225 vs. $58,889), a difference of $2,664 (P = 0.047). The five-year cost of angioplasty was significantly lower than that of surgery among patients with two-vessel disease ($52,930 vs. $58,498, P<0.05), but not among patients with three-vessel disease ($60,918 vs. $59,430). After five years of follow-up, surgery had an overall cost-effectiveness ratio of $26,117 per year of life added, but unacceptable ratios of $100,000 or more per year of life added could not be excluded (P = 0.13). Surgery appeared particularly cost effective in treating patients with diabetes because of their significantly improved survival. In patients with multivessel coronary disease, coronary-artery bypass surgery is associated with a better quality of life for three years than coronary angioplasty, after the initial morbidity caused by the procedure. Coronary angioplasty has a lower five-year cost than bypass surgery only in patients with two-vessel coronary disease.Keywords
This publication has 40 references indexed in Scilit:
- Comparison of Coronary Bypass Surgery with Angioplasty in Patients with Multivessel DiseaseNew England Journal of Medicine, 1996
- A meta-analysis of randomized trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty in multivessel coronary artery diseaseThe American Journal of Cardiology, 1995
- Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgeryThe Lancet, 1995
- First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation)The Lancet, 1995
- A Randomized Trial Comparing Coronary Angioplasty with Coronary Bypass SurgeryNew England Journal of Medicine, 1994
- A Randomized Study of Coronary Angioplasty Compared with Bypass Surgery in Patients with Symptomatic Multivessel Coronary DiseaseNew England Journal of Medicine, 1994
- Coronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosisThe Lancet, 1994
- Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): In-hospital results and 1-year follow-upJournal of the American College of Cardiology, 1993
- Coronary angioplasty versus coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trialThe Lancet, 1993
- Nonoperative Dilatation of Coronary-Artery StenosisNew England Journal of Medicine, 1979